Cancer incidence is rapidly growing worldwide. In 2020, there were an estimated 19.3 million new cases of cancer diagnosed, and the global cancer burden is expected to be 28.4 million cases in 2040, a substantial rise of 47%. Pain is one of the most frequent and disabling symptoms of cancer that can be caused by tumour and anticancer therapy. Cisplatin, a platinum-based chemotherapeutic used to treat solid tumours, is associated with a high incidence of chemotherapy-induced peripheral neuropathy and may affect up to 85% of treated patients reducing their quality of life. Thus, discovering new pharmacological targets for better managing pain caused by cisplatin is of great relevance.